Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium

AstraZeneca

Status: Completed

Conditions: Gastric Acid Suppression; Proton Pump Inhibitors

Study type: Observational

Funder types: Industry

Identifiers

NCT01130935

NIS-GAL-NEX-2010/1

Details and patient eligibility

About

This study will assess the effectiveness of Nexium at alleviating upper GI symptoms in subjects and evaluate with which treatment regimen and on which indications acid suppression with isomeric proton pump inhibitor is used in routine clinical practice in Albania.

Enrollment: 491 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject must have had upper GI symptoms requiring acid suppression treatment
• Treatment with Nexium is in accordance with indications and dosing approved in Albania.
• Start of treatment at least 2 weeks prior to enrollment to this study 5. Written informed consent is signed.

Exclusion criteria

• Known hypersensitivity to Nexium or any other constituents of the formulation
• Concomitant administration of atazanavir and nelfinavir.
• Alarming upper GI symptoms (i.e. significant unintended weight loss, vomiting, dysphasia, hematemesis, melena, fever, jaundice or any other sign indicating serious or malignant disease

Trial design

491 participants in 1 patient group

1